Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 107

Sort by

Sort Order Select

Journal Articles

Influence of TP53 gene mutations and their allelic status in myelodysplastic syndromes with isolated 5q deletion

Blood (2024) 144 (16): 1722–1731.

https://doi.org/10.1182/blood.2024023840

Published: 2024

Includes: Supplemental data

Journal Articles

ADAMTS13 recovery in acute thrombotic thrombocytopenic purpura after caplacizumab therapy

Blood (2024) 143 (18): 1807–1815.

https://doi.org/10.1182/blood.2023022725

Published: 2024

Includes: Supplemental data

Journal Articles

TP53 G ene a llelic State in Myelodysplastic Syndromes (MDS) with Isolated 5q Deletion

Blood (2023) 142 (Supplement 1): 1001.

https://doi.org/10.1182/blood-2023-179171

Published: 2023

Journal Articles

Multiomic Characterization of Myelodysplastic Neoplasms (MDS) with Micromegakaryocytes Highlights the Role of EZH2-RUNX1 deregulation in Disease Physiopathology and Response to Targeted Therapies

Blood (2023) 142 (Supplement 1): 4116.

https://doi.org/10.1182/blood-2023-188848

Published: 2023

Journal Articles

Ker-050 Treatment Reduced Iron Overload and Increased Bone Specific Alkaline Phosphatase in Participants with Lower-Risk MDS Supporting Potential to Restore Balance to the Osteohematopoietic Niche

Lynette C.Y. Chee, David M. Ross, Thomas Cluzeau, Shuhying Tan, Aristoteles Giagounidis, David Valcarcel, Montserrat Arnan, Maria Diez-Campelo, Christine Graham, Allie McGinty, Miranda Ross, Suresh Bobba, Wei Feng, Ying Jiang, Montagu Hankin, Christopher Rovaldi, Simon Cooper, Dena Grayson, Jen L. Salstrom

Blood (2023) 142 (Supplement 1): 1089.

https://doi.org/10.1182/blood-2023-186326

Published: 2023

Journal Articles

Efficacy and Safety of Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent (ESA)-Naive Patients (Pts) with Transfusion-Dependent (TD) Lower-Risk Myelodysplastic Syndromes (LR-MDS): Full Analysis of the COMMANDS Trial

Blood (2023) 142 (Supplement 1): 193.

https://doi.org/10.1182/blood-2023-178596

Published: 2023

Journal Articles

Results of Treatment Approaches in Myeloid Neoplasms According to TP53 Allelic Status (Multi-hit vs Monoallelic), a Real World Analysis

Maria Sola, Francisco Beas, Laura Palomo, Mar Tormo, Ana Riera, Nicolas Díaz Varela, Teresa Bernal, Sara García, Concepción Fernández, Nieves Garcia-Gisbert, Félix López Cadenas, Barbara Tazon, Adoracion Blanco, Sara Garrido Paniagua, Ana Pérez González, Andres Jerez, Julia Montoro, Olga Salamero, David Valcarcel

Blood (2023) 142 (Supplement 1): 3227.

https://doi.org/10.1182/blood-2023-187101

Published: 2023

Journal Articles

Clinical Impact of the New Bone Marrow Blasts Cutoff Defined By the International Classification Consortium (ICC) in Myeloid Neoplasms with Mutated TP53 gene

Blood (2023) 142 (Supplement 1): 3235.

https://doi.org/10.1182/blood-2023-181698

Published: 2023

Journal Articles

Prevalence, Dynamics and Clinical Significance of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Newly Diagnosed Cancer Patients

Blood (2023) 142 (Supplement 1): 5593.

https://doi.org/10.1182/blood-2023-189503

Published: 2023

Journal Articles

Clinical and Molecular Characterization of Patients with Therapy Related Myeloid Neoplasms (TRMN)

Blood (2023) 142 (Supplement 1): 3224.

https://doi.org/10.1182/blood-2023-188701

Published: 2023

Journal Articles

Durable Clinical Benefit with Ker-050 Treatment: Findings from an Ongoing Phase 2 Study in Participants with Lower-Risk MDS

Maria Diez-Campelo, David M. Ross, Aristoteles Giagounidis, Shuhying Tan, Thomas Cluzeau, Lynette C.Y. Chee, David Valcarcel, Montserrat Arnan, Christine Graham, Allie McGinty, Miranda Ross, Wei Feng, Ying Jiang, Suresh Bobba, Montagu Hankin, Christopher Rovaldi, Dena Grayson, Simon Cooper, Jen L. Salstrom

Blood (2023) 142 (Supplement 1): 196.

https://doi.org/10.1182/blood-2023-180974

Published: 2023

Journal Articles

Venetoclax and Azacytidine Treatment for High Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia As a Bridge Therapy to Transplant. a GESMD Study

Blood (2023) 142 (Supplement 1): 1858.

https://doi.org/10.1182/blood-2023-186777

Published: 2023

Journal Articles

Germline Predisposition in Myeloid Neoplasms Aged ≥50: A Novel Approach for Allogeneic Stem Cell -Transplantation Decision-Making

Blood (2023) 142 (Supplement 1): 5663.

https://doi.org/10.1182/blood-2023-179234

Published: 2023

Journal Articles

Clonal Hematopoiesis of Indeterminate Potential (CHIP) Related to the Etiology of Ischemic Stroke

Clàudia Pellín Jou, Jose Manuel Campos Zarraquiños, Laura Palomo, Carlos Lázaro Hernández, Marta Aurora Rubiera del Fueyo, Sara Garrido Paniagua, Sofia Laura Muzio, Maria Laura Fox, Pamela Acha, Prudencio Lozano Iragüen, David Valcarcel, Maria Julia Montoro, Francesc Bosch

Blood (2023) 142 (Supplement 1): 5601.

https://doi.org/10.1182/blood-2023-180508

Published: 2023

Journal Articles

Bispecific T-Cell Engagers for B-Cell NON-Hodgkin Lymphoma Patients before Allogeneic Stem Cell Transplantation. a Study on Behalf Od Geth-TC

Blood (2023) 142 (Supplement 1): 4899.

https://doi.org/10.1182/blood-2023-181815

Published: 2023

Journal Articles

Tolerability and Clinical Activity of Novel First in Class Oral Agent, Inobrodib (CCS1477), in Combination with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Blood (2023) 142 (Supplement 1): 2005.

https://doi.org/10.1182/blood-2023-174652

Published: 2023

Journal Articles

Caplacizumab Treatment in Elderly Patients with iTTP: Updated Experience from the Spanish TTP Registry

Blood (2023) 142 (Supplement 1): 5429.

https://doi.org/10.1182/blood-2023-180970

Published: 2023

Journal Articles

Effect of Caplacizumab in the Recovery of ADAMTS13 Level in Patients with Autoimmune Thrombotic Thrombocytopenic Purpura. Analysis from the Spanish Registry (REPTT)

Blood (2023) 142 (Supplement 1): 5394.

https://doi.org/10.1182/blood-2023-182876

Published: 2023

Journal Articles

Impact of Antibacterial Prophylaxis on Morbidity-Mortality of Patients with Myeloid Neoplasms Treated with Non-Intensive Venetoclax Combinations

Blood (2023) 142 (Supplement 1): 4270.

https://doi.org/10.1182/blood-2023-186762

Published: 2023

Journal Articles

Improvement of Patient-Reported Outcomes Among Heavily Pretreated Patients with Lower-Risk Myelodysplastic Syndromes and High Transfusion Burden Treated with Imetelstat on the IMerge Phase 3 Trial

Mikkael A. Sekeres, Maria Diez-Campelo, Amer M. Zeidan, Uwe Platzbecker, Antoine Regnault, Kristin Creel, Nishan Sengupta, Ying Wan, Libo Sun, Qi Xia, Tymara Berry, Souria Dougherty, Sheetal Shah, Shyamala Navada, Valeria Santini, David Valcárcel

Blood (2023) 142 (Supplement 1): 6479.

https://doi.org/10.1182/blood-2023-181103

Published: 2023

NARROW

Influence of TP53 gene mutations and their allelic status in myelodysplastic syndromes with isolated 5q deletion

ADAMTS13 recovery in acute thrombotic thrombocytopenic purpura after caplacizumab therapy

TP53 G ene a llelic State in Myelodysplastic Syndromes (MDS) with Isolated 5q Deletion

Multiomic Characterization of Myelodysplastic Neoplasms (MDS) with Micromegakaryocytes Highlights the Role of EZH2-RUNX1 deregulation in Disease Physiopathology and Response to Targeted Therapies

Ker-050 Treatment Reduced Iron Overload and Increased Bone Specific Alkaline Phosphatase in Participants with Lower-Risk MDS Supporting Potential to Restore Balance to the Osteohematopoietic Niche

Efficacy and Safety of Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent (ESA)-Naive Patients (Pts) with Transfusion-Dependent (TD) Lower-Risk Myelodysplastic Syndromes (LR-MDS): Full Analysis of the COMMANDS Trial

Results of Treatment Approaches in Myeloid Neoplasms According to TP53 Allelic Status (Multi-hit vs Monoallelic), a Real World Analysis

Clinical Impact of the New Bone Marrow Blasts Cutoff Defined By the International Classification Consortium (ICC) in Myeloid Neoplasms with Mutated TP53 gene

Prevalence, Dynamics and Clinical Significance of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Newly Diagnosed Cancer Patients

Clinical and Molecular Characterization of Patients with Therapy Related Myeloid Neoplasms (TRMN)

Durable Clinical Benefit with Ker-050 Treatment: Findings from an Ongoing Phase 2 Study in Participants with Lower-Risk MDS

Venetoclax and Azacytidine Treatment for High Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia As a Bridge Therapy to Transplant. a GESMD Study

Germline Predisposition in Myeloid Neoplasms Aged ≥50: A Novel Approach for Allogeneic Stem Cell -Transplantation Decision-Making

Clonal Hematopoiesis of Indeterminate Potential (CHIP) Related to the Etiology of Ischemic Stroke

Bispecific T-Cell Engagers for B-Cell NON-Hodgkin Lymphoma Patients before Allogeneic Stem Cell Transplantation. a Study on Behalf Od Geth-TC

Tolerability and Clinical Activity of Novel First in Class Oral Agent, Inobrodib (CCS1477), in Combination with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Caplacizumab Treatment in Elderly Patients with iTTP: Updated Experience from the Spanish TTP Registry

Effect of Caplacizumab in the Recovery of ADAMTS13 Level in Patients with Autoimmune Thrombotic Thrombocytopenic Purpura. Analysis from the Spanish Registry (REPTT)

Impact of Antibacterial Prophylaxis on Morbidity-Mortality of Patients with Myeloid Neoplasms Treated with Non-Intensive Venetoclax Combinations

Improvement of Patient-Reported Outcomes Among Heavily Pretreated Patients with Lower-Risk Myelodysplastic Syndromes and High Transfusion Burden Treated with Imetelstat on the IMerge Phase 3 Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only